Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
1655 | 6878 | 38.0 | 72% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
350 | 3 | COMPLEMENT//MANNOSE BINDING LECTIN//IMMUNOLOGY | 35656 |
1655 | 2 | BIOSIMILAR//FCRN//PROTEIN FORMULATION | 6878 |
4824 | 1 | AGALACTOSYL IGG//MABS//PROT ANALYT CHEM | 1719 |
8514 | 1 | PROTEIN FORMULATION//PROTEIN AGGREGATION//SUBVISIBLE PARTICLES | 1246 |
10569 | 1 | FCRN//NEONATAL FC RECEPTOR//TARGET MEDIATED DRUG DISPOSITION | 1052 |
11045 | 1 | ISOASPARTATE//DEAMIDATION//PROTEIN L ISOASPARTYL METHYLTRANSFERASE | 1012 |
14993 | 1 | BIOSIMILAR//ANTI ERYTHROPOIETIN ANTIBODIES//CT P13 | 737 |
18498 | 1 | BIOANALYSIS//ANTI DRUG ANTIBODIES//LIGAND BINDING ASSAY | 549 |
21074 | 1 | DYNAM MACROMOL ASSEMBLY SECT//ANALYTICAL ULTRACENTRIFUGATION//SEDIMENTATION VELOCITY | 434 |
33129 | 1 | IND BIOCHEM PROGRAM//BETA METHYLNORLEUCINE//CX 397 | 129 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | BIOSIMILAR | authKW | 728726 | 4% | 58% | 284 |
2 | FCRN | authKW | 491819 | 2% | 83% | 134 |
3 | PROTEIN FORMULATION | authKW | 434300 | 3% | 55% | 177 |
4 | MABS | journal | 253090 | 3% | 28% | 205 |
5 | NEONATAL FC RECEPTOR | authKW | 248985 | 1% | 84% | 67 |
6 | DEAMIDATION | authKW | 212692 | 2% | 35% | 138 |
7 | LATE STAGE PHARMACEUT DEV | address | 170386 | 1% | 80% | 48 |
8 | ISOASPARTATE | authKW | 159133 | 1% | 78% | 46 |
9 | PROTEIN AGGREGATION | authKW | 156083 | 4% | 13% | 274 |
10 | PROT ANALYT CHEM | address | 139877 | 1% | 52% | 61 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Biochemical Research Methods | 12978 | 15% | 0% | 1041 |
2 | Pharmacology & Pharmacy | 12195 | 26% | 0% | 1794 |
3 | Chemistry, Analytical | 6800 | 15% | 0% | 1007 |
4 | Biochemistry & Molecular Biology | 4517 | 25% | 0% | 1688 |
5 | Immunology | 4041 | 13% | 0% | 907 |
6 | Chemistry, Medicinal | 3094 | 7% | 0% | 480 |
7 | Biotechnology & Applied Microbiology | 1306 | 7% | 0% | 500 |
8 | Chemistry, Multidisciplinary | 1232 | 12% | 0% | 795 |
9 | Medicine, Research & Experimental | 1039 | 6% | 0% | 395 |
10 | Biophysics | 840 | 5% | 0% | 351 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | LATE STAGE PHARMACEUT DEV | 170386 | 1% | 80% | 48 |
2 | PROT ANALYT CHEM | 139877 | 1% | 52% | 61 |
3 | ANALYT FORMULAT SCI | 118390 | 1% | 68% | 39 |
4 | PROC PROD DEV | 104295 | 1% | 44% | 54 |
5 | MACROMOL VACCINE STABILIZAT | 90640 | 1% | 55% | 37 |
6 | FORMULAT ANALYT OURCES | 87419 | 0% | 73% | 27 |
7 | FORMULAT SCI | 80393 | 1% | 42% | 43 |
8 | LATE STAGE PHARMACEUT PROC DEV | 73016 | 0% | 69% | 24 |
9 | DYNAM MACROMOL ASSEMBLY SECT | 67248 | 0% | 63% | 24 |
10 | EARLY STAGE PHARMACEUT DEV | 63229 | 0% | 51% | 28 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | MABS | 253090 | 3% | 28% | 205 |
2 | BIOANALYSIS | 125815 | 3% | 14% | 199 |
3 | JOURNAL OF PHARMACEUTICAL SCIENCES | 70188 | 6% | 4% | 422 |
4 | AAPS JOURNAL | 58234 | 2% | 11% | 122 |
5 | PHARMACEUTICAL RESEARCH | 21485 | 3% | 2% | 198 |
6 | BIOLOGICALS | 13673 | 1% | 5% | 65 |
7 | BIOPHARM INTERNATIONAL | 12834 | 1% | 7% | 39 |
8 | JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS | 10827 | 1% | 6% | 38 |
9 | MOLECULAR IMMUNOLOGY | 9659 | 2% | 2% | 125 |
10 | PROGRESS IN COLLOID AND POLYMER SCIENCE | 8029 | 0% | 13% | 14 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | BIOSIMILAR | 728726 | 4% | 58% | 284 | Search BIOSIMILAR | Search BIOSIMILAR |
2 | FCRN | 491819 | 2% | 83% | 134 | Search FCRN | Search FCRN |
3 | PROTEIN FORMULATION | 434300 | 3% | 55% | 177 | Search PROTEIN+FORMULATION | Search PROTEIN+FORMULATION |
4 | NEONATAL FC RECEPTOR | 248985 | 1% | 84% | 67 | Search NEONATAL+FC+RECEPTOR | Search NEONATAL+FC+RECEPTOR |
5 | DEAMIDATION | 212692 | 2% | 35% | 138 | Search DEAMIDATION | Search DEAMIDATION |
6 | ISOASPARTATE | 159133 | 1% | 78% | 46 | Search ISOASPARTATE | Search ISOASPARTATE |
7 | PROTEIN AGGREGATION | 156083 | 4% | 13% | 274 | Search PROTEIN+AGGREGATION | Search PROTEIN+AGGREGATION |
8 | SUBVISIBLE PARTICLES | 111549 | 0% | 93% | 27 | Search SUBVISIBLE+PARTICLES | Search SUBVISIBLE+PARTICLES |
9 | TARGET MEDIATED DRUG DISPOSITION | 102393 | 0% | 77% | 30 | Search TARGET+MEDIATED+DRUG+DISPOSITION | Search TARGET+MEDIATED+DRUG+DISPOSITION |
10 | ANTI ERYTHROPOIETIN ANTIBODIES | 97811 | 0% | 96% | 23 | Search ANTI+ERYTHROPOIETIN+ANTIBODIES | Search ANTI+ERYTHROPOIETIN+ANTIBODIES |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | GIRAGOSSIAN, C , CLARK, T , PICHE-NICHOLAS, N , BOWMAN, CJ , (2013) NEONATAL FC RECEPTOR AND ITS ROLE IN THE ABSORPTION, DISTRIBUTION, METABOLISM AND EXCRETION OF IMMUNOGLOBULIN G-BASED BIOTHERAPEUTICS.CURRENT DRUG METABOLISM. VOL. 14. ISSUE 7. P. 764-790 | 223 | 73% | 14 |
2 | SOCKOLOSKY, JT , SZOKA, FC , (2015) THE NEONATAL FC RECEPTOR, FCRN, AS A TARGET FOR DRUG DELIVERY AND THERAPY.ADVANCED DRUG DELIVERY REVIEWS. VOL. 91. ISSUE . P. 109 -124 | 132 | 84% | 13 |
3 | MANNING, MC , CHOU, DK , MURPHY, BM , PAYNE, RW , KATAYAMA, DS , (2010) STABILITY OF PROTEIN PHARMACEUTICALS: AN UPDATE.PHARMACEUTICAL RESEARCH. VOL. 27. ISSUE 4. P. 544 -575 | 190 | 38% | 312 |
4 | WARD, ES , DEVANABOYINA, SC , OBER, RJ , (2015) TARGETING FCRN FOR THE MODULATION OF ANTIBODY DYNAMICS.MOLECULAR IMMUNOLOGY. VOL. 67. ISSUE 2. P. 131 -141 | 117 | 84% | 8 |
5 | ROOPENIAN, DC , AKILESH, S , (2007) FCRN: THE NEONATAL FC RECEPTOR COMES OF AGE.NATURE REVIEWS IMMUNOLOGY. VOL. 7. ISSUE 9. P. 715 -725 | 75 | 87% | 676 |
6 | LIU, HC , PONNIAH, G , ZHANG, HM , NOWAK, C , NEILL, A , GONZALEZ-LOPEZ, N , PATEL, R , CHENG, GL , KITA, AZ , ANDRIEN, B , (2014) IN VITRO AND IN VIVO MODIFICATIONS OF RECOMBINANT AND HUMAN IGG ANTIBODIES.MABS. VOL. 6. ISSUE 5. P. 1145 -1154 | 122 | 79% | 13 |
7 | MARTINS, JP , KENNEDY, PJ , SANTOS, HA , BARRIAS, C , SARMENTO, B , (2016) A COMPREHENSIVE REVIEW OF THE NEONATAL FC RECEPTOR AND ITS APPLICATION IN DRUG DELIVERY.PHARMACOLOGY & THERAPEUTICS. VOL. 161. ISSUE . P. 22 -39 | 136 | 66% | 1 |
8 | KUO, TT , BAKER, K , YOSHIDA, M , QIAO, SW , AVESON, VG , LENCER, WI , BLUMBERG, RS , (2010) NEONATAL FC RECEPTOR: FROM IMMUNITY TO THERAPEUTICS.JOURNAL OF CLINICAL IMMUNOLOGY. VOL. 30. ISSUE 6. P. 777 -789 | 95 | 86% | 88 |
9 | VIDARSSON, G , DEKKERS, G , RISPENS, T , (2014) IGG SUBCLASSES AND ALLOTYPES: FROM STRUCTURE TO EFFECTOR FUNCTIONS.FRONTIERS IN IMMUNOLOGY. VOL. 5. ISSUE . P. - | 101 | 52% | 100 |
10 | LIU, HC , GAZA-BULSECO, G , FALDU, D , CHUMSAE, C , SUN, J , (2008) HETEROGENEITY OF MONOCLONAL ANTIBODIES.JOURNAL OF PHARMACEUTICAL SCIENCES. VOL. 97. ISSUE 7. P. 2426-2447 | 126 | 56% | 172 |
Classes with closest relation at Level 2 |